Zhang X, Pang T, Zhang H, Horn M, Michlits G, Dyczynski M
Sci Rep. 2024; 14(1):20509.
PMID: 39227746
PMC: 11372130.
DOI: 10.1038/s41598-024-71722-7.
Yu K, Xiang L, Li S, Wang S, Chen C, Mu H
Anim Cells Syst (Seoul). 2019; 23(5):326-334.
PMID: 31700698
PMC: 6830197.
DOI: 10.1080/19768354.2019.1658637.
Hiroshige T, Eguchi Y, Yoshizumi O, Chikui K, Kumagai H, Kawaguchi Y
Oncol Lett. 2018; 15(5):6806-6814.
PMID: 29725416
PMC: 5920147.
DOI: 10.3892/ol.2018.8263.
Geng J, Lin V, Yu C, Huang C, Yin H, Chang T
Int J Mol Sci. 2016; 17(12).
PMID: 27898031
PMC: 5187770.
DOI: 10.3390/ijms17121970.
Chi K, Kheoh T, Ryan C, Molina A, Bellmunt J, Vogelzang N
Ann Oncol. 2015; 27(3):454-60.
PMID: 26685010
PMC: 4769990.
DOI: 10.1093/annonc/mdv594.
Genetic variants of the autophagy pathway as prognostic indicators for prostate cancer.
Huang C, Huang S, Lin V, Yu C, Chang T, Lu T
Sci Rep. 2015; 5:14045.
PMID: 26365175
PMC: 4568463.
DOI: 10.1038/srep14045.
Knockdown of NOB1 expression inhibits the malignant transformation of human prostate cancer cells.
Zhang X, Zhang D, Qu F, Hong Y, Cao J, Pan X
Mol Cell Biochem. 2014; 396(1-2):1-8.
PMID: 25169742
DOI: 10.1007/s11010-014-2126-z.
PARP-1 and CASP3 genes are up-regulated in LNCaP and PC-3 prostate cancer cell lines.
Salemi M, Condorelli R, La Vignera S, Barone N, Ridolfo F, Giuffrida M
Hum Cell. 2014; 27(4):172-5.
PMID: 25037599
DOI: 10.1007/s13577-013-0076-5.
Molecular imaging of urogenital diseases.
Cho S, Szabo Z
Semin Nucl Med. 2014; 44(2):93-109.
PMID: 24484747
PMC: 3912464.
DOI: 10.1053/j.semnuclmed.2013.10.008.
Antibody Microarray Analysis of Signaling Networks Regulated by Cxcl13 and Cxcr5 in Prostate Cancer.
El-Haibi C, Singh R, Gupta P, Sharma P, Greenleaf K, Singh S
J Proteomics Bioinform. 2013; 5(8):177-184.
PMID: 24009409
PMC: 3760521.
DOI: 10.4172/jpb.1000232.
A comparison of the biological features of prostate cancer with (PSA+, PSMA+) profile according to RKIP.
Ben Jemaa A, Bouraoui Y, Sallami S, Nouira Y, Oueslati R
Biomed Res Int. 2013; 2013:409179.
PMID: 23991415
PMC: 3749534.
DOI: 10.1155/2013/409179.
Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue.
Salemi M, Galia A, Fraggetta F, La Corte C, Pepe P, La Vignera S
Eur J Histochem. 2013; 57(2):e13.
PMID: 23807292
PMC: 3794339.
DOI: 10.4081/ejh.2013.e13.
DPP4 genetic variants influence baseline prostate-specific antigen levels: the J-MICC study.
Higashibata T, Naito M, Mori A, Ozawa N, Furuta M, Tsuchiya R
Nagoya J Med Sci. 2013; 75(1-2):73-80.
PMID: 23544270
PMC: 4345699.
Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer.
Calcagno F, Nguyen T, Dobi E, Villanueva C, Curtit E, Kim S
Clin Med Insights Oncol. 2013; 7:1-12.
PMID: 23362372
PMC: 3547543.
DOI: 10.4137/CMO.S7256.
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.
Cho S, Gage K, Mease R, Senthamizhchelvan S, Holt D, Jeffrey-Kwanisai A
J Nucl Med. 2012; 53(12):1883-91.
PMID: 23203246
PMC: 3742115.
DOI: 10.2967/jnumed.112.104661.
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.
Pienta K, Machiels J, Schrijvers D, Alekseev B, Shkolnik M, Crabb S
Invest New Drugs. 2012; 31(3):760-8.
PMID: 22907596
DOI: 10.1007/s10637-012-9869-8.
The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development.
Corn P
Cancer Manag Res. 2012; 4:183-93.
PMID: 22904640
PMC: 3421469.
DOI: 10.2147/CMAR.S32839.
Prevalence of prostate cancer metastases after intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment.
Jung Y, Shiozawa Y, Wang J, McGregor N, Dai J, Park S
Neoplasia. 2012; 14(5):429-39.
PMID: 22745589
PMC: 3384430.
DOI: 10.1596/neo.111740.
Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype.
Joseph J, Shiozawa Y, Jung Y, Kim J, Pedersen E, Mishra A
Mol Cancer Res. 2012; 10(3):282-92.
PMID: 22241219
PMC: 3307952.
DOI: 10.1158/1541-7786.MCR-11-0404.
Use of androgen deprivation therapy in prostate cancer: indications and prevalence.
Connolly R, Carducci M, Antonarakis E
Asian J Androl. 2012; 14(2):177-86.
PMID: 22231299
PMC: 3735079.
DOI: 10.1038/aja.2011.103.